Compared with the possible adverse effects of LT4 treatment, including cardiovascular events and symptoms associated with excess thyroid hormone, such as nervousness and palpitations (53), the credible efficacy with high safety margins (54, 55) of RES make it a promising candidate for the treatment of SCH-associated depression. The gene discussed is TG; the disease is major depressive disorder.